Showing 6 posts of 6 posts found.


Takeda and TiGenix’s Alofisel becomes first donor-derived stem cell therapy approved in Europe

March 26, 2018
Sales and Marketing Crohn’s disease, EU, Europe, European Commission, Takeda, TiGenix, crohn's disease, pharma

The European Commission has awarded approval to Takeda and TiGenix’s allogeneic expanded adipose-derived stem cell (eASC) therapy Alofisel (darvadstrocel) for …

Takeda agrees $630m takeover of TiGenix

January 5, 2018
Medical Communications, Sales and Marketing Takeda, TiGenix, biotech, drugs, pharma, pharmaceutical

Takeda already had a strong working relationship with TiGenix, after previously signing a licensing agreement with the Belgium-based pharma company …


TiGenix announces success of novel heart attack stem cell trial

March 13, 2017
Research and Development, Sales and Marketing Stem cells, TiGenix, heart attack

Belgium’s TiGenix has announced the success of its top-line Phase 2/3 study investigating the effects of donor-derived expanded cardiac stem …


Takeda and TiGenix announce successful trial of Crohn’s disease drug

February 17, 2017
Medical Communications, Sales and Marketing Takeda, TiGenix

Takeda and TiGenix announced Phase 3 results from a trial looking into the investigational compound Cx601, a treatment for refractory …

TiGenix says additional data for stem cell product affirms safety profile

March 9, 2016
Research and Development Crohn’s disease, TiGenix, crohn's disease, drug trial

Belgian biotech firm TiGenix said the results of a 52-week follow-up study of its trial drug for a stem-cell condition …

Lonza image

TiGenix and Lonza partner on stem cell manufacturing

February 13, 2015
Manufacturing and Production, Sales and Marketing Crohn’s disease, Lonza, Stem cells, TiGenix, crohn's disease, eascs, manufacturing, spa

Stem cell therapy developer TiGenix has enlisted the help of biologics manufacturer Lonza to produce its medicine Cx601 for late-stage …

Latest content